CA
NZ
UK
AU
IND
US
…
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
STAAR Surgical develops and sells implantable intraocular lenses, mainly phakic ICLs (EVO/Visian) made from proprietary Collamer material to correct myopia and other refractive errors. Long-term growth may be supported by rising myopia prevalence, aging populations, expanded approvals and wider international adoption, and the company appears positioned as a niche market leader with differentiated technology and recurring procedure demand.
Top risks are slower-than-expected surgical adoption, intensifying competition from laser and alternative lens technologies, potential clinical or regulatory setbacks, and execution or supply-chain disruptions.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-01-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-01-31 | 2022-12-31 |
| Income before tax | -82.26M | -9.05M | 33.70M | 45.80M | 45.55M |
| Net income | -80.45M | -20.21M | 21.35M | 39.01M | 39.66M |
| Selling general administrative | 85.78M | 89.90M | 72.32M | 54.74M | 54.74M |
| Selling and marketing expenses | 102.53M | 108.32M | 107.83M | 88.86M | 88.86M |
| Gross profit | 182.42M | 239.58M | 252.65M | 223.38M | 223.38M |
| Reconciled depreciation | 8.73M | 6.89M | 5.12M | 4.51M | 4.51M |
| Ebit | -82.26M | -9.05M | 33.70M | 43.80M | 45.55M |
| Ebitda | -73.53M | -2.16M | 38.82M | 50.02M | 50.06M |
| Depreciation and amortization | 8.73M | 6.89M | 5.12M | 6.22M | 4.51M |
| Operating income | -45.95M | -12.61M | 28.10M | 43.80M | 43.80M |
| Other operating expenses | 285.39M | 326.51M | 294.32M | 240.59M | 240.59M |
| Interest expense | - | - | - | 2.45M | 2.45M |
| Tax provision | -1.81M | 11.16M | 12.35M | 6.80M | 6.80M |
| Interest income | 4.59M | 5.91M | 6.99M | - | 2.45M |
| Net interest income | 4.59M | 5.91M | 6.99M | 2.45M | 2.45M |
| Income tax expense | -1.81M | 11.16M | 12.35M | 6.80M | 5.89M |
| Total revenue | 239.44M | 313.90M | 322.42M | 284.39M | 284.39M |
| Total operating expenses | 228.37M | 252.19M | 224.55M | 179.58M | 179.58M |
| Cost of revenue | 57.02M | 74.32M | 69.76M | 61.01M | 61.01M |
| Total other income expense net | -36.32M | 3.56M | 5.60M | 2.00M | 1.75M |
| Net income from continuing ops | -80.45M | -20.21M | 21.35M | 39.01M | 39.01M |
| Net income applicable to common shares | - | - | - | 38.76M | 38.76M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2024-01-31 | 2023-12-31 | 2023-01-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2024-01-31 | 2023-12-31 | 2023-01-31 |
| Total assets | 461.62M | 509.52M | 488.69M | 488.69M | 415.15M |
| Intangible assets | 30.70M | 15.76M | - | - | 0.17M |
| Other current assets | 13.91M | 14.88M | 11.43M | 11.43M | 13.73M |
| Total liab | 117.44M | 112.19M | 102.74M | 102.74M | 82.71M |
| Total stockholder equity | 344.18M | 397.33M | 385.95M | 385.95M | 332.44M |
| Other current liab | 51.06M | 43.12M | 36.26M | 36.26M | 36.45M |
| Common stock | 0.50M | 0.49M | 0.49M | 0.49M | 0.48M |
| Capital stock | 0.50M | 0.49M | 0.49M | 0.49M | 0.48M |
| Retained earnings | -148.02M | -67.58M | -47.37M | -47.37M | -72.39M |
| Other liab | - | - | - | - | 3.64M |
| Good will | 1.79M | 1.79M | 1.79M | 1.79M | 1.79M |
| Other assets | - | - | - | - | 5.78M |
| Cash | 153.15M | 144.16M | 183.04M | 183.04M | 86.48M |
| Total current liabilities | 68.50M | 70.31M | 65.04M | 65.04M | 51.72M |
| Current deferred revenue | - | - | 10.85M | 10.85M | - |
| Net debt | -114.80M | -105.42M | -147.20M | -147.20M | -55.44M |
| Short term debt | 5.87M | 3.94M | 4.37M | 4.37M | 3.69M |
| Short long term debt total | 38.35M | 38.74M | 35.83M | 35.83M | 31.04M |
| Other stockholder equity | 498.22M | 471.45M | 436.95M | 436.95M | 404.19M |
| Property plant equipment | - | - | - | - | 81.53M |
| Total current assets | 311.55M | 367.94M | 365.27M | 365.27M | 311.97M |
| Long term investments | - | 0.00M | 11.70M | 11.70M | 13.90M |
| Net tangible assets | - | - | - | - | 330.23M |
| Short term investments | 34.39M | 86.33M | 37.69M | 37.69M | 125.16M |
| Net receivables | 54.61M | 79.26M | 97.98M | 97.98M | 62.45M |
| Inventory | 55.50M | 43.30M | 35.13M | 35.13M | 24.16M |
| Accounts payable | 11.57M | 16.70M | 13.56M | 13.56M | 11.58M |
| Accumulated other comprehensive income | -6.51M | -7.03M | -4.11M | -4.11M | 0.16M |
| Non currrent assets other | 1.35M | 17.23M | 3.34M | 3.34M | 0.96M |
| Non current assets total | 150.07M | 141.58M | 123.42M | 123.42M | 103.17M |
| Capital lease obligations | 38.35M | 38.74M | 35.83M | 35.83M | 31.04M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2024-01-31 | 2023-12-31 | 2023-01-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2024-01-31 | 2023-12-31 | 2023-01-31 |
| Investments | 52.16M | -59.22M | 74.35M | 74.35M | -156.38M |
| Change to liabilities | - | - | - | - | 1.80M |
| Total cashflows from investing activities | 46.34M | -59.22M | - | 74.35M | -156.38M |
| Net borrowings | -0.04M | -0.17M | - | -0.16M | -0.13M |
| Total cash from financing activities | -4.55M | 5.72M | 7.42M | 7.42M | 8.30M |
| Change to operating activities | - | - | - | - | -3.14M |
| Net income | -80.45M | -20.21M | 21.35M | 21.35M | 39.01M |
| Change in cash | 8.99M | -38.88M | 96.56M | 96.56M | -113.23M |
| Begin period cash flow | 144.16M | 183.04M | 86.48M | 86.48M | 199.71M |
| End period cash flow | 153.15M | 144.16M | 183.04M | 183.04M | 86.48M |
| Total cash from operating activities | -34.23M | 15.72M | 14.59M | 14.59M | 35.72M |
| Issuance of capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Depreciation | 8.32M | 6.89M | 5.12M | 5.12M | 4.51M |
| Other cashflows from investing activities | 0.20M | 1.09M | - | - | - |
| Dividends paid | - | - | 0.01M | 0.01M | - |
| Change to inventory | -16.98M | -0.01M | -14.36M | -14.36M | -7.94M |
| Change to account receivables | 27.83M | 0.02M | -32.76M | -32.76M | -19.60M |
| Sale purchase of stock | -6.46M | -1.50M | -2.10M | -2.10M | 0.00M |
| Other cashflows from financing activities | -1.52M | 7.39M | 0.01M | 9.67M | 8.42M |
| Change to netincome | - | - | - | - | 21.28M |
| Capital expenditures | 5.82M | 23.39M | 18.19M | 18.19M | 18.11M |
| Change in working capital | -16.33M | -5.40M | -40.84M | -40.84M | -29.13M |
| Stock based compensation | 30.59M | 27.21M | 23.52M | 23.52M | 20.37M |
| Other non cash items | 26.55M | 3.64M | 2.18M | 2.18M | 2.30M |
| Free cash flow | -40.05M | -7.67M | -3.59M | -3.59M | 17.61M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| STAA STAAR Surgical Company |
0.23 0.92% |
25.17 | 280.56 | 52.36 | 3.31 | 3.17 | 2.98 | 19.91 |
| ISRG Intuitive Surgical Inc |
3.88 0.89% |
440.75 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
-2.00 0.95% |
208.00 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
-1.89 1.80% |
103.04 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
-0.66 0.33% |
197.94 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
25510 Commercentre Drive, Lake Forest, CA, United States, 92630
626 303 7902
921
| Name | Title | Year Born |
|---|---|---|
| Ms. Caren L. Mason | CEO, Pres & Director | 1954 |
| Mr. Patrick F. Williams | Chief Financial Officer | 1973 |
| Dr. Keith Holliday | Chief Technology Officer | 1963 |
| Mr. Hans-Martin Blickensdoerfer | Consultant | 1965 |
| Dr. Scott D. Barnes M.D. | Chief Medical Officer | 1963 |
| Mr. Brian Moore | VP of Investor, Media Relations & Corp. Devel. | NA |
| Mr. Samuel J. Gesten | Chief Legal Officer & Corp. Sec. | 1962 |
| Mr. James Francese | Sr. VP of Commercial Operations - North America & APAC | 1964 |
| Joanne Egamino Ph.D. | Global Head of Clinical Operations | NA |
| Mr. Philippe Subrin | VP of Collamer Lens Manufacturing & GM of Nidau Operations | 1964 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.39%
Communication Services
+0.40%
Consumer Cyclical
-0.20%
Consumer Defensive
-0.56%
Energy
-0.45%
Financial Services
-0.09%
Financials
+0.11%
Healthcare
+0.40%
Industrials
+0.34%
Real Estate
-0.14%
Technology
+0.88%
Utilities
+0.11%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...